Evaluate efficacy clinical trials phase ii as topic. Medical search. Frequent questions

Home page Questions and answers Statistics Donations Contact

Anatomy1

Cell Line, Tumor

Organisms1

Diseases44

Neoplasms Lung Neoplasms Disease Progression Neoplasm Metastasis Breast Neoplasms Neoplasm Recurrence, Local Recurrence Nausea Neutropenia Carcinoma, Non-Small-Cell Lung Leukopenia Brain Neoplasms Colorectal Neoplasms Drug-Related Side Effects and Adverse Reactions Thrombocytopenia Vomiting Melanoma Prostatic Neoplasms Ovarian Neoplasms Disease Models, Animal Pain HIV Infections Hematologic Diseases Acute Disease Stroke Fatigue Kidney Neoplasms Diarrhea Chronic Disease Liver Neoplasms Stomach Neoplasms Peritoneal Neoplasms Carcinoma, Renal Cell Head and Neck Neoplasms Carcinoma, Squamous Cell Pancreatic Neoplasms Glioblastoma Glioma Sarcoma Carcinoma, Small Cell Carcinoma Biliary Tract Neoplasms Lymphoma, Non-Hodgkin Asthenia

Chemicals and Drugs76

Antineoplastic Agents Deoxycytidine Placebos Paclitaxel Cisplatin Fluorouracil Taxoids Antibodies, Monoclonal, Humanized Antineoplastic Agents, Phytogenic Camptothecin Antibodies, Monoclonal Organoplatinum Compounds Drug Combinations Carboplatin Antimetabolites, Antineoplastic Doxorubicin Quinazolines Vinblastine Dacarbazine Leucovorin Drugs, Investigational Antineoplastic Agents, Alkylating Benzenesulfonates Cyclophosphamide Phenylurea Compounds Angiogenesis Inhibitors Niacinamide Etoposide Epothilones Protein Kinase Inhibitors Pyridines Tegafur Pyrroles Pyrimidines Recombinant Proteins Anti-Bacterial Agents Pyrazines Thalidomide Oxonic Acid Cancer Vaccines Epirubicin Vincristine Biological Markers Ifosfamide Thiophenes Piperazines Indoles Methotrexate Sulfonamides Antibodies, Monoclonal, Murine-Derived Antibiotics, Antineoplastic Tumor Markers, Biological Triazoles Immunosuppressive Agents NAD(P)H Dehydrogenase (Quinone)Quinolines Benzamides Bridged Compounds Prednisone Boronic Acids Anthracyclines Interferon-alpha Anticarcinogenic Agents Immunologic Factors Anti-Inflammatory Agents Polyethylene Glycols Piperidines Guanine Sirolimus Pyrazoles Plant Extracts Granulocyte Colony-Stimulating Factor Antineoplastic Agents, Hormonal Biomarkers, Pharmacological Antiviral Agents Estramustine

Analytical, Diagnostic and Therapeutic Techniques and Equipment82

Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase III as Topic Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Double-Blind Method Research Design Clinical Trials, Phase I as Topic Randomized Controlled Trials as Topic Infusions, Intravenous Controlled Clinical Trials as Topic Disease-Free Survival Survival Analysis Drug Evaluation Administration, Oral Patient Selection Follow-Up Studies Prospective Studies Placebos Combined Modality Therapy Multicenter Studies as Topic Drug Therapy, Combination Survival Rate Clinical Protocols Single-Blind Method Endpoint Determination Pilot Projects Maximum Tolerated Dose Clinical Trials, Phase IV as Topic Neoplasm Staging Sample Size Feasibility Studies Kaplan-Meier Estimate Early Termination of Clinical Trials Severity of Illness Index Prognosis Salvage Therapy Remission Induction Treatment Failure Questionnaires Chemotherapy, Adjuvant Risk Factors Risk Assessment Meta-Analysis as Topic Reproducibility of Results Pain Measurement Retrospective Studies Cross-Over Studies Injections, Intravenous Phytotherapy Area Under Curve Drug Approval Random Allocation Drug Evaluation, Preclinical Immunotherapy Disease Models, Animal Neoadjuvant Therapy Data Interpretation, Statistical Injections, Subcutaneous Analysis of Variance Molecular Targeted Therapy Administration, Topical Exercise Therapy Drug Delivery Systems Predictive Value of Tests Genetic Therapy Statistics, Nonparametric Cohort Studies Probability Interviews as Topic Sensitivity and Specificity Radiotherapy, Adjuvant Chemoprevention Xenograft Model Antitumor Assays Injections, Intramuscular Statistics as Topic Magnetic Resonance Imaging Therapeutic Human Experimentation Proportional Hazards Models Multivariate Analysis Models, Statistical

Psychiatry and Psychology3

Patient Compliance Pain Cognitive Therapy

Phenomena and Processes12

Metabolic Detoxication, Phase II Time Factors Dose-Response Relationship, Drug Maximum Tolerated Dose Drug Resistance, Neoplasm Area Under Curve Pain Probability Sensitivity and Specificity Pregnancy Drug Synergism Algorithms

Disciplines and Occupations8

Research Design Evidence-Based Medicine Outcome Assessment (Health Care)Biomedical Research Medical Oncology Statistics as Topic Therapeutic Human Experimentation Translational Medical Research

Anthropology, Education, Sociology and Social Phenomena7

Quality of Life Patient Education as Topic Drug Approval Informed Consent United States Food and Drug Administration National Institutes of Health (U.S.)National Cancer Institute (U.S.)

Technology, Industry, Agriculture3

Dietary Supplements Drug Industry Polyethylene Glycols

Humanities1

Quality of Life

Information Science12

Survival Rate Periodicals as Topic Questionnaires Review Literature as Topic Abstracting and Indexing as Topic Data Interpretation, Statistical Textbooks as Topic Terminology as Topic Publishing Interviews as Topic Internet Algorithms

Named Groups3

Research Subjects Patient Dropouts Infant, Newborn

Health Care68

Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase III as Topic Double-Blind Method Clinical Trials, Phase I as Topic Randomized Controlled Trials as Topic Controlled Clinical Trials as Topic Disease-Free Survival Survival Analysis Patient Selection Follow-Up Studies Prospective Studies Multicenter Studies as Topic Survival Rate Clinical Protocols Single-Blind Method Pilot Projects Clinical Trials, Phase IV as Topic Clinical Trials Data Monitoring Committees Sample Size Feasibility Studies Kaplan-Meier Estimate Early Termination of Clinical Trials Severity of Illness Index Safety Congresses as Topic Treatment Failure Questionnaires Guidelines as Topic Cost-Benefit Analysis Risk Factors Risk Assessment Outcome Assessment (Health Care)Meta-Analysis as Topic Reproducibility of Results Patient Education as Topic Patient Compliance Practice Guidelines as Topic Retrospective Studies Cross-Over Studies Area Under Curve Random Allocation Data Interpretation, Statistical Intention to Treat Analysis Placebo Effect Informed Consent United States Food and Drug Administration Analysis of Variance Research Support as Topic Patient Satisfaction Patient Participation Predictive Value of Tests Benchmarking Statistics, Nonparametric Cohort Studies Probability Interviews as Topic Sensitivity and Specificity Age Factors Bias (Epidemiology)National Institutes of Health (U.S.)National Cancer Institute (U.S.)Statistics as Topic Proportional Hazards Models Multivariate Analysis Models, Statistical Societies, Medical

Geographicals2

United States Europe

Anatomy Organisms Diseases Chemicals and Drugs Analytical, Diagnostic and Therapeutic Techniques and Equipment Psychiatry and Psychology Phenomena and Processes Disciplines and Occupations Anthropology, Education, Sociology and Social Phenomena Technology, Industry, Agriculture Humanities Information Science Named Groups Health Care Geographicals

Clinical Trials as Topic Clinical Trials, Phase II as Topic Treatment Outcome Clinical Trials, Phase III as Topic Drug Administration Schedule Antineoplastic Combined Chemotherapy Protocols Double-Blind Method Research Design Clinical Trials, Phase I as Topic Antineoplastic Agents Metabolic Detoxication, Phase II Randomized Controlled Trials as Topic Infusions, Intravenous Controlled Clinical Trials as Topic Time Factors Neoplasms Disease-Free Survival Dose-Response Relationship, Drug Survival Analysis Deoxycytidine Drug Evaluation Administration, Oral Patient Selection Follow-Up Studies Prospective Studies Placebos Paclitaxel Combined Modality Therapy Multicenter Studies as Topic Cisplatin Drug Therapy, Combination Survival Rate Fluorouracil Taxoids Lung Neoplasms Antibodies, Monoclonal, Humanized Disease Progression Clinical Protocols Antineoplastic Agents, Phytogenic Single-Blind Method Endpoint Determination Pilot Projects Neoplasm Metastasis Camptothecin Maximum Tolerated Dose Antibodies, Monoclonal Organoplatinum Compounds Breast Neoplasms Neoplasm Recurrence, Local Clinical Trials, Phase IV as Topic Neoplasm Staging Clinical Trials Data Monitoring Committees Evidence-Based Medicine Sample Size Quality of Life Feasibility Studies United States Drug Combinations Carboplatin Recurrence Kaplan-Meier Estimate Nausea Antimetabolites, Antineoplastic Neutropenia Carcinoma, Non-Small-Cell Lung Leukopenia Early Termination of Clinical Trials Severity of Illness Index Doxorubicin Prognosis Quinazolines Periodicals as Topic Salvage Therapy Vinblastine Dacarbazine Safety Remission Induction Congresses as Topic Treatment Failure Drug Resistance, Neoplasm Leucovorin Questionnaires Guidelines as Topic Drugs, Investigational Cost-Benefit Analysis Antineoplastic Agents, Alkylating Chemotherapy, Adjuvant Risk Factors Risk Assessment Benzenesulfonates Outcome Assessment (Health Care)Brain Neoplasms Meta-Analysis as Topic Cyclophosphamide Phenylurea Compounds Colorectal Neoplasms Drug-Related Side Effects and Adverse Reactions Biomedical Research Reproducibility of Results Review Literature as Topic

No FAQ available that match "evaluate efficacy clinical trials phase ii as topic"